Coya Therapeutics (COYA) Research & Development (2022 - 2026)
Coya Therapeutics (COYA) posted Research & Development of $4.1 million for Q1 2026, down 17.08% sequentially from $4.9 million in Q4 2025, and down 21.43% YoY from $5.2 million in Q1 2025.
Coya Therapeutics (COYA) Research & Development (2022 - 2026) Analysis & Trends
Coya Therapeutics has reported Research & Development for 5 years, with the latest figure at $4.1 million in Q1 2026.
- Quarterly Research & Development fell 21.43% year-over-year to $4.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.6 million (up 12.02% YoY) and the FY2025 annual result came in at $16.7 million, up 41.03% from the prior year.
- Research & Development fell to $4.1 million in Q1 2026 per COYA's latest filing, from $4.9 million in the prior quarter.
- Over five years, Research & Development peaked at $5.2 million in Q1 2025 and troughed at $708032.0 in Q4 2022.
- A 5-year average of $2.5 million and a median of $1.9 million in 2024 frame the typical range for Research & Development.
- The sharpest annual moves came in 2023 and 2024: Research & Development slipped 26.21% in 2023, then jumped 327.56% in 2024.
- Over 5 years, Research & Development stood at $708032.0 in 2022, then soared by 127.34% to $1.6 million in 2023, then grew by 20.37% to $1.9 million in 2024, then surged by 155.0% to $4.9 million in 2025, then decreased by 17.08% to $4.1 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $4.1 million, $4.9 million, and $2.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Coya Therapeutics | 113.30 Mn | 70.10 Mn | - | 5.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.03 Mn |
| Mar 31, 2026 | 4.10 Mn |
| Dec 31, 2025 | 4.94 Mn |
| Sep 30, 2025 | 2.92 Mn |
| Jun 30, 2025 | 3.66 Mn |
| Mar 31, 2025 | 5.21 Mn |
| Dec 31, 2024 | 1.94 Mn |
| Sep 30, 2024 | 2.22 Mn |
| Jun 30, 2024 | 4.57 Mn |
| Mar 31, 2024 | 3.14 Mn |
| Dec 31, 2023 | 1.61 Mn |
| Sep 30, 2023 | 1.59 Mn |
| Jun 30, 2023 | 1.07 Mn |
| Mar 31, 2023 | 1.23 Mn |
| Dec 31, 2022 | 708,032.00 |
| Sep 30, 2022 | 1.28 Mn |
| Jun 30, 2022 | 1.45 Mn |
| Mar 31, 2022 | 978,804.00 |